Moreover, although all reported cases of IMT used lorlatinib in later lines of treatment [65, 99, 108, 109], lorlatinib has shown superior efficacy as a first-line treatment treating ALK+ NSCLC compared to crizotinib in the CROWN trial (NCT03052608) [110]. This evidence concerns the gene ALK and non-small cell lung carcinoma.